Laneta Dorflinger, PhD

FHI 360 | Distinguished Scientist and Director, Contraceptive Technology Innovation

Laneta Dorflinger, PhD, is a Distinguished Scientist and the Director of Contraceptive Technology Innovation at FHI 360. A passionate advocate for expanding reproductive choice for nearly 35 years, Dr. Dorflinger has spent her career advancing contraceptive technology research, development, and introduction with a focus on low- and middle-income countries. She currently leads a multimillion-dollar program to develop and introduce new mid- to long‐acting contraceptive methods to meet the needs of women in low-resource settings.

Since joining FHI 360 in 1991, Dr. Dorflinger has held several leadership positions, including Vice President of Clinical Research, Vice President of Research and Development, Director of Clinical Trials, and Director of Regulatory Affairs and Quality Assurance. Immediately prior to her current role, she directed the Preventive Technologies Agreement—a USAID‐funded global program to characterize safety and effectiveness of microbicides and oral pre‐exposure prophylaxis (PrEP), expand understanding of the interface between prevention technology and behavior, and improve service delivery models for integrating family planning and HIV.

Dr. Dorflinger began her career at the U.S. Agency for International Development, where she focused on the development, introduction, and post‐marketing assessments of Norplant®, Jadelle®, and Mirena®, cutting-edge technologies of the time.

Dr. Dorflinger earned her undergraduate degree in chemistry from Lafayette College and her PhD in physiology from Yale University. She also did post‐doctoral training at the Harvard School of Public Health. She has received several noteworthy awards, including the Science and Technology in Development award from USAID, and the George Washington Kidd Award for career distinction and an honorary Doctor of Sciences from her alma mater, Lafayette College.